Loeb Holding Corporation

Parachute Health is a provider of medical equipment ordering software. Their mission is to improve patient care through transparent and seamless coordination of medical equipment and supplies.

Gravy Analytics is the leading provider of real-world location intelligence for marketers. Their patented AdmitOneTM engine verifies consumer attendances at millions of places, points-of-interest, and local events, providing unprecedented visibility into the offline consumer journey.

BetterPT is a platform technology company committed to transforming patient access and experience with healthcare services by providing end-to-end digital connectivity between physicians, physical therapists and patients. The company’s unique marketplace model, which includes interoperable, HIPAA compliant technology with EMR compatibility, enables patients greater access to physical therapy, an important and oftentimes overlooked part of clinical rehabilitation and preventive care. Partnering with the world leader in musculoskeletal health, the Hospital for Special Surgery (HSS), BetterPT has grown to support thousands of PT practices across the U.S., also offering a number of operational efficiencies and solutions to providers.

NuLabel Technologies is a polymer science and engineering innovations company developing innovative label and packaging solutions to help companies cut costs and reduce waste. label has developed patented adhesive and patent-pending hardware technology that uses activatable adhesives to eliminate the need for a label's non-stick liner backing or the need for messy wet glue used in product packaging. The company was founded in 2009 and headquartered in East Providence, Rhode Island.

Relationship Science (RelSci) is a technology solutions company that helps individuals and organizations leverage their relationships for a competitive business advantage. The RelSci platform provides deep information about over 6 million influential decision makers - who they are and who they know, what you have in common with them, and how you can gain access to them and their organizations. Our relationship mapping tool empowers you to discover new relationships, advance existing ones, and maximize every opportunity.

WaveMark, Inc. provides information products that enable hospitals and manufacturers to control and manage the flow of consumable medical devices. Its product enables to capture, store, and provide data via Web browser for manufacturers and hospitals. The company uses radio frequency identification technology to collect and report real time information in a hands free environment. WaveMark, Inc. was founded in 2003 and is based in Littleton, Massachusetts

Therion Biologics Corporation is focusing on the development and commercialization of innovative vaccines for the treatment of major cancers. Currently, Therion has two lead products moving into pivotal clinical trials in the next two years: PROSTVAC-VF for prostate cancer, developed by Therion, and ALVAC-CEA/B7.1, developed in collaboration with Aventis Pasteur Ltd., for colorectal cancer. The company also has a broad pipeline of vaccines in early clinical development for treatment of other major cancers, including breast cancer, lung cancer, melanoma and other solid tumors. Therion's partners include Aventis Pasteur, the National Cancer Institute and a network of leading clinical institutions around the world. Therion is a privately-held biotechnology company headquartered in Cambridge, Massachusetts. Therion's goal is to generate safe and effective therapeutic cancer vaccines that stimulate the immune system to specifically attack cancer cells, and thereby stabilize disease or induce tumor regression, improve patients' quality of life, and increase patient survival. While there has been significant progress in the treatment of some cancers, the prognosis for many cancer patients remains poor. For example, colorectal cancer affects an estimated 130,000 new patients and accounts for 56,300 deaths each year in the United States. Prostate cancer is the second leading cause of cancer death in men, with an estimated 180,400 new cases and 31,900 deaths in the U.S. annually. Recent advances in immunology and tumor biology have opened the door for the development of new generation therapeutic cancer vaccines. In particular, scientists now have a better understanding of the key molecular signals involved in eliciting potent and specific immune responses. This allows researchers to engineer vaccines that induce elements of the immune system required to eliminate cancer cells. Therion is at the forefront, quickly moving leading research into clinical development. Capitalizing on these recent scientific advances, Therion is targeting many of the major cancers currently lacking adequate treatment. Therion's therapeutic cancer vaccines for breast, lung, colorectal and prostate cancers, and melanoma address a majority of the large and rapidly growing market for cancer treatments.

Cubitz.com online solution for companies seeking business space.